Study on Heart Function Changes in Cancer Patients Treated with Nivolumab or Pembrolizumab

1 1 1 1

What is this study about?

This clinical trial focuses on studying the effects of certain cancer treatments on heart function. The diseases being studied are various types of cancer. The treatments involved in this study are two medications: nivolumab and pembrolizumab. These medications are part of a group of drugs known as immunotherapies, which help the body’s immune system fight cancer. Nivolumab is also known by the code names BMS936558 and ABP 206, while pembrolizumab is known by several code names, including Lambrolizumab and MK-3475.

The purpose of the study is to observe how the heart’s left ventricle, a chamber responsible for pumping blood, functions over time in patients receiving these treatments. This is done by monitoring patients in a specialized unit that focuses on the heart health of cancer patients, known as a Cardio-Oncology unit. The study will track changes in heart function using a specific measurement called the global longitudinal strain value, which helps assess how well the heart muscle is working.

Participants in the study will receive either nivolumab or pembrolizumab through an intravenous infusion, which means the medication is given directly into a vein. The study will last for a period of up to six months, during which the heart function of the participants will be regularly monitored. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments. The study aims to provide valuable information on how these cancer treatments might affect heart health, helping to improve care for future patients.

1 joining the study

Upon joining the study, eligibility is confirmed based on criteria such as being selected to receive treatment with nivolumab or pembrolizumab and affiliation with a national insurance scheme.

2 treatment administration

Receive treatment with either nivolumab or pembrolizumab. Both medications are administered through an intravenous infusion.

The specific dosage, frequency, and duration of administration are determined by the healthcare provider based on individual needs and treatment protocols.

3 monitoring cardiac function

The main objective is to monitor the evolution of the heart’s left ventricular function during the treatment.

This is measured by the global longitudinal strain value, which helps assess heart function over time.

4 follow-up

Regular follow-up appointments are scheduled to track the progress of the treatment and the heart’s response.

These appointments are conducted in a Cardio-Oncology unit, where specialized care is provided.

5 completion of the study

The study is estimated to conclude by October 8, 2026.

Upon completion, a final assessment of the heart’s function is conducted to evaluate the overall impact of the treatment.

Who Can Join the Study?

Patients must have cancer.
Patients must be selected to receive treatment with nivolumab or pembrolizumab. These are medications used to treat certain types of cancer.
Patients must be affiliated with a national insurance scheme, meaning they should have health insurance provided by the government or a similar organization.
Both male and female patients can participate.
Patients of all ages, except for very young children, are eligible.
Patients should not be part of a vulnerable population, which means they should not be in a group that needs special protection or care.

Who Cannot Join the Study?

Patients who do not have a diagnosis of cancer cannot participate.
Patients who are not within the specified age range cannot participate. The age range is not specified here, but it is important for eligibility.
Patients who are part of a vulnerable population cannot participate. A vulnerable population includes groups that may need special protection, like children or people with certain disabilities.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country	Status
Azvjdhelsb Puhlwyre Htavrymr Dz Mwcxhnzkb	Marseille	France

Trial status

Country	Status	Recruitment Start
France	Recruiting	09.04.2018

Trial locations

Investigated drugs:

Nivolumab is a type of cancer treatment known as immunotherapy. It works by helping your immune system recognize and attack cancer cells. This medication is used to treat various types of cancer by blocking a protein called PD-1, which can prevent the immune system from attacking cancer cells.

Pembrolizumab is another immunotherapy medication that helps your immune system fight cancer. Like nivolumab, it targets the PD-1 protein, allowing your immune system to better detect and destroy cancer cells. This treatment is used for different kinds of cancer and is part of the study to observe its effects on heart function.

Cancer – Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. If the spread is not controlled, it can interfere with essential bodily functions. Cancer can develop in almost any organ or tissue, such as the lung, colon, breast, skin, bones, or nerve tissue. The progression of cancer varies depending on the type and location, but it generally involves the growth of a primary tumor, which may invade nearby tissues and spread to distant parts of the body through the bloodstream or lymphatic system. The rate of progression can be slow or rapid, and symptoms may not appear until the disease is advanced.

Trial ID:

2024-517403-36-00

NCT ID:

NCT03313544

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Heart Function Changes in Cancer Patients Treated with Nivolumab or Pembrolizumab

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?